Vistagen reports positive fasedienol data in very severe social anxiety at Psych Congress 2026

Vistagen Therapeutics, Inc.

Post-hoc PALISADE-4 Phase 3 analysis showed statistically significant SUDS improvement in very severe SAD (LSAS >=95) despite missed primary endpoint in overall population.
Phase 2a repeat-dose study prespecified analysis: significant SUDS improvement after single dose; greater numerical improvement after second dose taken 10 minutes later.
Second-dose data also showed significant improvements in anticipatory anxiety pre-PSC in both overall and very severe populations.
Safety in very severe subgroup consistent with prior trials; no serious drug-related signals identified.
Data presented at Psych Congress 2026 in New Orleans; supports fasedienol's potential for LSAS >=95 patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.